innohep 18,000 iu in 0.9 ml, solution for injection
leo laboratories limited - tinzaparin sodium - solution for injection - 18,000 iu in 0.9 ml international unit(s)/millilitre - heparin group; tinzaparin
spiriva 18 microgram inhalation powder, hard capsule
imed healthcare ltd. - tiotropium - inhalation powder, hard capsule - 18 microgram(s) - anticholinergics; tiotropium bromide
spiriva 18 microgram inhalation powder, hard capsule
pco manufacturing ltd. - tiotropium - inhalation powder, hard capsule - 18 microgram(s) - anticholinergics; tiotropium bromide
spiriva 18 microgram, inhalation powder, hard capsule
imbat limited - tiotropium bromide - inhalation powder, hard capsule - 18 microgram(s) - anticholinergics; tiotropium bromide
srivasso 18 microgram, inhalation powder, hard capsule
boehringer ingelheim international gmbh - tiotropium - inhalation powder, hard capsule - 18 microgram(s) - anticholinergics; tiotropium bromide
ceporex 18 %w/v suspension for injection
intervet ireland limited - cefalexin sodium - suspension for injection - 18 percent weight/volume - cefalexin - cattle, dogs, cats - antibacterial
panacur equine oral paste 18.75 %w/w
intervet ireland limited - fenbendazole - oral paste - 18.75 percent weight/weight - fenbendazole - horses - endoparasiticide
lecteva levodopa/carbidopa/entacapone 75 mg/18.75 mg/200 mg tablet bottle
teva pharma australia pty ltd - levodopa, quantity: 75 mg; carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; hypromellose; titanium dioxide; glycerol; iron oxide yellow; polysorbate 80; iron oxide red - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.
levofloxacin tablet, film coated
zydus pharmaceuticals (usa) inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 250 mg - levofloxacin tablet is indicated in adult patients for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1)] . levofloxacin tablet is indicated in adult patients for the treatment of community-acquired pneumonia due to methicillin-susceptible staphylococcus aureus, streptococcus pneumoniae (including multi-drug-resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, haemophilus parainfluenzae, klebsiella pneumoniae, moraxella catarrhalis, chlamydophila pneumoniae, legionella pneumophila, or mycoplasma pneumoniae [see dosage and administration (2.1) and clinical studies (14.2)] . mdrsp isolat
levofloxacin tablet, film coated
apotheca inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 750 mg - levofloxacin tablets, usp are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. levofloxacin tablets, usp are indicated for the treatment of nosocomial pneumonia due to methicillinsusceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae. adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an antipseudomonal β-lactam is recommended [see clinical studies ( 14.1) ]. levofloxacin tablets, usp are indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible staphylococcus aureus , streptococcus pneumoniae (including multidrug-resistant